Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing

BACKGROUND: Tumor mutational burden (TMB) is emerging as a promising biomarker in immune checkpoint inhibitor (ICI) therapy. Despite whole-exome sequencing (WES) being the gold standard for quantifying TMB, TMB is determined by selected targeted panels in most cases, and WES-derived TMB data are lac...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chuang, Chen, Song, Xu, Fei, Wei, Jinwang, Zhou, Xiaoyu, Wu, Zhiqiang, Zhao, Longshuan, Liu, Jun, Guo, Wenbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506705/
https://www.ncbi.nlm.nih.gov/pubmed/34733989
http://dx.doi.org/10.21037/atm-21-4227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506705/
https://www.ncbi.nlm.nih.gov/pubmed/34733989
http://dx.doi.org/10.21037/atm-21-4227

Ejemplares similares